Drug waste minimization as an effective strategy of cost-containment in Oncology by Gianpiero Fasola et al.
Fasola et al. BMC Health Services Research 2014, 14:57
http://www.biomedcentral.com/1472-6963/14/57RESEARCH ARTICLE Open AccessDrug waste minimization as an effective strategy
of cost-containment in Oncology
Gianpiero Fasola1*, Giuseppe Aprile1, Luisa Marini2, Alessandro Follador1, Mauro Mansutti1 and Manuela Miscoria1,3Abstract
Background: Sustainability of cancer care is a crucial issue for health care systems worldwide, even more during a
time of economic recession. Low-cost measures are highly desirable to contain and reduce expenditures without
impairing the quality of care. In this paper we aim to demonstrate the efficacy of drug waste minimization in
reducing drug-related costs and its importance as a structural measure in health care management.
Methods: We first recorded intravenous cancer drugs prescription and amount of drug waste at the Oncology
Department of Udine, Italy. Than we developed and applied a protocol for drug waste minimization based on
per-pathology/per-drug scheduling of chemotherapies and pre-planned rounding of dosages.
Results: Before the protocol, drug wastage accounted for 8,3% of the Department annual drug expenditure. Over
70% of these costs were attributable to six drugs (cetuximab, docetaxel, gemcitabine, oxaliplatin, pemetrexed and
trastuzumab) that we named ‘hot drugs’. Since the protocol introduction, we observed a 45% reduction in the
drug waste expenditure. This benefit was confirmed in the following years and drug waste minimazion was able to
limit the impact of new pricely drugs on the Department expenditures.
Conclusions: Facing current budgetary constraints, the application of a drug waste minimization model is effective
in drug cost containment and may produce durable benefits.
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The burden of cancer is increasing, producing skyrocket-
ing costs which have a significant impact on health care
expenditure in all developed countries. Urgent solutions
to contain those costs are necessary and range from re-
engineering the macroeconomic basis of cancer spending
(e.g. value-based approaches to bend the cost curve and
allow cost saving technologies), educating policy makers,
introducing transparent and equitable regulatory systems,
and adopting validated outcomes in both clinical trials
and processes of drug approval [1,2].
The ASCO statement on the spiralling costs of cancer
care suggest that the multiple factors lying beneath the
rising expenditures in Oncology are a consequence of
insufficient integration and coordination in health care
systems [3]. Among possible solutions, measures to
help oncologists to use cost-effectiveness information* Correspondence: fasola.gianpiero@aoud.sanita.fvg.it
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reproduction in any medium, provided the orand discuss drug costs with their patients have been
advocated [4].
In 2007 cancer costs accounted for around 6% of health
care costs in Europe [5]. Total attributable expenses of can-
cer care include direct costs, such as drug expenditure, and
indirect costs, mainly loss of productivity in individuals of
working age [6].
Although prescription drug expenditure is only a small
percentage of health care costs [6], antineoplastics alone
represent a significant and growing part of this spending
(~15% [5]) and are the leading category in hospital drugs
expenses [7]. Even though few data are available, drug-
related expenditure is proportionally higher in Oncology
than in other medical specialities and overcome staffing
costs for outpatients care [8,9].
Between 2005 and 2006 a 20% increase in cancer drug
costs was observed in the U.S., mainly caused by the intro-
duction of novel targeted therapies, such as bevacizumab,
cetuximab and trastuzumab [10]. Similar reports have been
produced in other Countries [11]. Furthermore, in the lasttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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FDA exceeded $ 20,000 for 12 weeks of treatment [12],
rising sparkling debates on their cost-effectiveness [13].
During an economic recession, the rising costs of
cancer treatment make therapeutic recommendations
and cancer care management more complex. However,
this is not a recession-specific issue, and middle in-
come countries that are establishing universal drug
coverage programs are also dealing with this dilemma
[14,15]. European countries have faced the problem in
many different ways: - through a government direct price
control (Greece, France, Spain); - through a risk sharing
policy (Italy); - through a ‘value-based’ pricing scheme
(UK, Germany) [16]. In this scenario, the development
of additional, low-cost measures to contain and reduce
expenditures, such as drug waste reduction and human
resources optimization, are highly desirable. Drug waste
consists of the either unavoidable or inappropriate
clearance of partially used ampoules, vials, syringes of
drugs [17]. We have previously shown that a protocol
including a centralized drug use surveillance combined
with a intravenous (iv) chemotherapies scheduling by
tumour type on different days and a planned dose
rounding (up to 5% of the calculated dose [18]) is able
to provide significant decreases in drug waste costs
within the first year of application [19]. In 2005 at the
Oncology Department of the University Hospital of
Udine, the cost of iv consumed drugs reached 2,147,169
€ with 8.3% of this expenditure (corresponding to
179,576 €) being attributable to drug waste. About 74%
of all drug waste costs (133,292 €), corresponding to
6.2% of the Department drug costs, was attributable to six
compounds (hereafter defined as ‘hot drugs’): cetuxi-
mab, docetaxel, gemcitabine, oxaliplatin, pemetrexed
and trastuzumab. After the introduction of specific
corrective measures [20], the total waste costs progres-
sively dropped down, cutting by half the annual cost of
waste. Still, over 80% of the waste expenditure was due
to the six ‘hot drugs’. However, their waste decreased
significantly (around 68%) leading to a reduction in the
overall cost of waste, that was reduced to 4% of the global
drug expenditure at that point [20].
In the present study we aimed to:
1. verify if the model may endure for a longer time,
and confirm if the results we have obtained after the
first year of application may further hold up
2. test if the virtual loop created by the application of
the model may absorb an external disturbance. This
was obtained with the evaluation of the impact
produced by the introduction of new high-cost IV
drugs in the clinical practice;
3. analyze potential pitfalls and propose new strategies
to improve the final outcomes.Methods
The Department of Oncology at the University Hospital
of Udine is a fully computerized, research-oriented clinical
unit with approximately 1,500 new cases per year. The
Department annual drug expenditure, defined as the
sum of iv drug, including waste, plus oral cancer agents
plus residual drug deposit) was 6,178,000 € in 2011.
Drug dilutions for the whole Hospital are carried out
at a centralized Antiblastic Drugs Unit (ADU). All pre-
scribed chemotherapies are recorded in the computer
system. This way pharmacists and technicians double
check and record all the prescriptions (drug doses,
dose rounding and reductions) at the ADU. The aver-
age number of diluted cycles per month for the whole
hospital is over 1,300, with an average of 800 cycles per
month (range in the years 2007-2009: 763-821) for the
Oncology Department only.
Starting 2005, the number of monthly dilutions of all
the iv drugs, day prescriptions and actual consumption
have been recorded, calculating the actual use and the
waste. The projected waste cost for the year and its pro-
portion, compared to the overall pharmaceutical expend-
iture, have been calculated for the most expensive drugs.
After a period of observation, in January 2006 we in-
troduced a protocol of waste reduction, which consists
of four corrective measures:
1. a per pathology/per drug distribution of
chemotherapy sessions over the week;
2. the choice of multi-dose vials, able to maintain
micro-biological and chemical stability for up to
24 hours;
3. the rounding of drug dosages within 5% of the
calculated dose [18,21]
4. the selection of the most convenient vial size,
according to the drug unit price and to an accurate
estimate of the daily use of each drug.
Starting July 2006, observation was focused on the six
drugs which had shown to have the largest impact in terms
of drug waste costs (cetuximab, docetaxel, gemcitabine,
oxaliplatin, pemetrexed and trastuzumab), accounting for
88% of the waste costs and 3.5% of the Department annual
drug costs. Those compounds were defined as ‘hot drugs’
since they had the highest impact on our annual budget
due to both high unitary cost per milligram and increas-
ingly high volumes of utilization. After approval in clin-
ical practice and in the light of the high cost and the
predicted increased prescription, we included bevacizu-
mab (from 2007) and panitumumab (from 2009) in our
analysis. Thus a total of 32 different drugs were consid-
ered: waste related to the 8 ‘hot drugs’ was registered
monthly, while the one derived from the other 24 drugs
on a six-month bases. Any decrease in negotiated drug
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account in the economic analysis when comparing drug
waste costs along the year.
In the current study we present the results of the 3 years
follow up.
Results
We present the results of the cost-containment policy
study split into years. Average figures of monthly dilutions
were consistent during the years of observation. The
Department drug costs, observed iv drug costs and
waste costs are synthesized in Table 1.
What happened in 2007
After the introduction of bevacizumab among the moni-
tored compounds, their total waste costs was € 51,441,
with an average per month of € 4,287. For the other 24
drugs included in the analysis, average drug waste cost
per month was € 1,877. In just one year (2007) € 24,347
were saved from the waste of the monitored ‘hot drugs’,
corresponding to a 32% cost reduction. Notably, 71%
of the total waste expenditures may be attributed to
pemetrexed and trastuzumab. Cost of waste for bevaci-
zumab represented 7.9% of the expenditures of the ‘hot
drugs’ (€ 4,056).
What happened in 2008
During 2008, the total waste cost for the ‘hot drugs’ were
consistent with 2007, being of € 53,386. In 2008, total
savings amounted to € 22,402, corresponding to a percent-
age reduction of drug waste cost of 29%. Once again, 87%
of the waste expenditures came from pemetrexed and tras-
tuzumab. Notably, whilst we observed an increase in pre-
scriptions and dilutions of pemetrexed (+39.5%), docetaxel
(+14%), gemcitabine (+9.5%), oxaliplatin (+21.7%) and bev-
acizumab (+61%), the overall drug waste expenditures for
the seven ‘hot drugs’ remained comparable to that of 2007.
This can be partially justified by a concurrent decrease of
cetuximab (-10%) and trastuzumab (-11.6%) prescriptions.
In 2008 cetuximab waste accounted for 3.5% (€ 2,680)
and trastuzumab waste for 18.8% (€ 14,283) of the total
cost of waste.
What happened in 2009
The introduction of panitumumab in our analysis (2009)
was linked to a total waste expenditure for this drug of €
1,046 (2%).Table 1 Costs during the protocol application
2005 2006
iv drugs 2,147.169€ 2,109.392€
Whole waste 179,576€ (8,3%) 85,982€ (4%)
Hot drugs waste 133,292€ (6,2%) 75,788€ (3,5%)During 2009 total cost savings for the eight ‘hot drugs’
were consistent with the previous years (€ 21,067 corre-
sponding to a 27.8% reduction on 2006 costs).
Compared to 2008, in 2009 we recorded a significant
increase in prescriptions of pemetrexed (+34.8%), cetuxi-
mab (+35%), oxaliplatin (+44.5%) and bevacizumab (+60%).
Pemetrexed and trastuzumab were responsible themselves
for 50.6% (€ 31,901) and 21.7% (€ 13,707) of the total waste
costs Figures 1 and 2.
In 2009 the negotiated price of oxaliplatin decreased
sensibly, due to patent expiry. Thus we analysed the waste
percentage per month and the consequent cost of waste in
2008 and 2009. During 2008 the waste cost of oxaliplatin
accounted for 0.8% of the whole expenditures (€ 421). After
the price reduction, this cost decreased in 2009 to € 110
(0.2%). However, despite an increase in the prescription of
oxaliplatin of 44% compared to 2008, even if the price per
milligram had remained the same as in the previous year,
in 2009 the total cost for oxaliplatin waste would have
accounted only for 1.5% of the total expenditure (€ 807).
Discussion
How a simple cost-saving policy may fit in the
current landscape
The rising cost of cancer care has progressively become
hardly sustainable [22]. Whether will be possible to contain
health care costs while maintaining open access to cure and
without worsening the results of cancer care is uncertain
[2,20]. The continuing progress in oncology has to face an
increasing need of rationalization of expenses. Many of the
strategies proposed to reduce health care cost are medium
to long term possible solutions whose impact on expendi-
tures is barely predictable [23]. Low cost measures with a
rapid effect on spending containment and able to optimize
human and economic resources are highly desirable.
We have previously shown how a simple policy of
drug waste control may significantly decrease the impact
on the overall pharmaceutical expenditures and allow a
substantial cost saving in the short time. In the present
study, we also demonstrate that these measures can pro-
vide a long lasting benefit, although slightly diluted with
time. Moreover, the application of the proposed model
can reduce the impact of the waste of expensive drugs
on the rise of costs.
Notably, monitoring the 24 drugs with low impact on
cost of waste, we observed that waste expenditure was
less than € 2,000 per month. Thus, with the protocol2007 2008 2009
3,062.369€ 3,383.658€ 3,471.665€
73,975€ (2,4%) 75,909€ (2,2%) 62,994€ (1,8%)














drug waste cost (€)
Figure 1 Pemetrexed waste cost compared to its prescription.
Fasola et al. BMC Health Services Research 2014, 14:57 Page 4 of 7
http://www.biomedcentral.com/1472-6963/14/57application, the waste for the non-hot drugs accounted
for around 2-3% of their global cost. This percentage
can be considered as the most favourable result from
the protocol application and could be adopted as a
benchmark to compare the efficiency of the model in
waste costs containment.
In 2005 drug wastage accounted for 8.3% of the
Department annual drug expenditure, corresponding
to € 179,576. If the same percentage of drug wasting
had been confirmed in the following years, the cost
of wastage would have accounted for € 175,079 in
2007, € 280,243 in 2008 and € 288,248 in 2009 Table 2;
Figures 3, 4 and 5.
Most waste costs were due to six ‘hot drugs’ (cetuximab,
docetaxel, gemcitabine, oxaliplatin, pemetrexed and
trastuzumab). After the introduction of waste limiting
measures, in 2006 we observed a meaningful reduction
(45%) in drug waste expenditure. This benefit was con-









Figure 2 Trastuzumab waste cost compared to its prescription.the ‘hot drugs’ waste, the application of our protocol
produced a saving of € 24,347 in 2007, € 22,403 in 2008
and € 21,067 in 2009 (that is 32%, 29% and 27% of the iv
drugs waste costs) in addiction to over € 90,000 per annum
saved since 2006 (when comparing to the pre-protocol era)
even after the introduction of new high cost drugs.
After the inclusion in our observation of panitumumab
(2009), despite the high-cost per mg (4.2 €/mg in Italy),
within the protocol its prescription did not cause any in-
crease in drug waste expenditures (accounting for 1.6%).
These results suggest that not only the price per milli-
gram (mg) is a critical element in drug waste control,
but also the mgs wasted themselves. This is further sup-
ported by the trend in the cost of waste of oxaliplatin. In
this case the price per mg substantially decreased in 2009
and the total amount of its waste cost declined consist-
ently with price reduction. However, compared to the total
waste costs, oxaliplatin waste accounted for a very small
percentage (less than € 1,000 per month).umab
009
drug prescribing (mg)
drug waste cost (€)
Table 2 Calculated savings per year
2006 2007 2008 2009
Waste
Estimated 175,079€ 254,176€ 280,843€ 288,148€
Observed 85,982€ 73,975€ 75,909€ 62,994€
Saving 89,097€ 180,201€ 204,934€ 225,154€
Hot drugs waste
Estimated 130,782€ 189,866€ 209,786€ 215,243€
Observed 75,788€ 51,441 53,385€ 54,721€
Saving 54,994€ 138,425€ 156,400€ 160,522€
(Estimated = calculated on 2005 waste percentage; Observed = with drug
waste minimization).
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eral drugs (pemetrexed, docetaxel, gemcitabine, oxaliplatin,
bevacizumab), the proportion of waste did not change. This
evidence supports the efficacy of our protocol in containing
drug wastage and reducing its costs, independently of the
amount of drug prescribed.
During the 3 years of observation, the greatest amount
of waste expenditures came from pemetrexed and tras-
tuzumab. Thus, according to our experience, after a
period of waste recording and observation, the moni-
toring of these two drugs is effective in estimating
overall drug wastage.
In particular, pemetrexed prescriptions have increased
during 2008 as a result of the approval of metastatic
NSCLC in the first line treatment by the Italian Drugs
Monitoring Controlling Body (AIFA). In light of the
observation that wasted mgs have a decisive influence
on the total waste expenditure per drug, the high rate
of pemetrexed wastage can be attributable to the dose
per ampoule which did not allow a favourable rounding.
Starting 2010, pemetrexed has been available in 100 mg












Figure 3 Comparison between iv Drug Costs and Waste Costs after thfurther reduced waste. If it is confirmed that ampoules
dosages have a strong influence in drugs wastage, in future
at the time of negotiation with the Drug Companies, atten-
tion should be paid not only to price per mg, but also to
mg per ampoule, drug stability and vials.
Our protocol on drug waste minimization has proved
to be effective in drug costs containment and to be consist-
ent and with durable results. It would be thus interesting to
verify the reproducibility of these results in other hospitals.
In fact, the observation ended in 2009 after almost 4 years
of follow up. This experience was extended to a large
number of prescriptions and dilutions and the results we
observed in 2007, 2008 and 2009 were reliable in terms of
drug waste savings.
Limitations of the study
Limitations of our study include that it is a monocentric
experience, carried out in a fully computerized clinical
unit. In our point of view, an adequate computer system
and a centralized ADU are required for the application
of the protocol, together with an adequate training of
the personnel involved. Secondly, we did not considered
the impact of oral high-cost drugs on drug expendi-
tures, which may need a specific protocol to evaluate
the amount of drug waste and related costs and ad-hoc
measures to reduce them. Moreover we have to con-
sider that, in the near future, the fraction of iv drugs
will proportionally decrease, and the availability of bio-
similar cancer drugs will also help reducing the costs
[24,25] Finally, after a significant decrease in wastage
costs during the first year of application of the proto-
col, the benefit tends to reach a plateau, with smaller
savings during the second and third year. On the other
hand this can be positively interpreted as the ability of
the system to maintain its steady state after the first
phase of optimization, supporting the robustness of our
measures with time.h the Protocol
2007 2008 2009
Observed Waste Cost
e application of the protocol.









2006 2007 2008 2009
Observed Waste Cost Waste Cost without the protocol
Figure 4 Waste Costs observed and estimated without the protocol adoption.
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Possible future developments of our protocol include
the evaluation of the efficacy of dose rounding other
than 5% of the whole dose. In fact, whilst this rounding
is validated for chemotherapy agents [21], and it has
been recently suggested that biologic agents rounding
would be the same [26]. Recent data suggest that up to
10% rounding can be effective, with no detrimental
effect on drug efficacy [27]. Based on preclinical and
early clinical data on the anticancer activity of biologic
products [28,29], Winger et al. showed how dose round-
ing to a value within 10% of the ordered doses could
produce a 42% reduction in drug wastage. Effective
drug-target interactions, neutralizing antibody forma-
tion and biologic characteristics of the disease impact
on drug activity more than drug dosage itself. Thus, the
amount of administered drug should be adequate to
yield systemic concentrations that will optimally satur-
ate or modulate the target. The application of these ob-
servations to our protocol might further increase drug





Observed Waste Costs € 179,576 85,
Estimated Waste Costs € 179,576 175
2005 20
Figure 5 Comparison between Observed Waste Costs and Estimatedapproaching strategy may be applied to oral cancer agents
(both chemotherapies and biologics) to save remnants
and further reduce healthcare costs. In conclusion, the
present study demonstrates that drug waste surveillance is
a low-cost, effective and lasting measure to substantially
reduce intravenous antineoplastic expenditures.
Conclusions
We have shown how the application of a simple drug
waste minimization model may consent to cut by half
the whole drug waste expenditures. Facing current
budgetary constraints, this policy was effective in cost
containment and produced long-lasting benefits. Our
experience represents a contribution towards the sus-
tainability of the costs of cancer care and its value in
cost-containment could be proven and better quanti-
fied through multicentric experiences on larger areas.
Among major suggested changes of the oncologists’
behaviour in attitudes and practice [20], we think that
low-cost measures producing a more responsible drug
prescription may be highly attractive.2009
Observed Waste Costs €
Estimated Waste Costs €
982 73,975 75,909 62,994
,079 254,176 280,843 288,148
06 2007 2008 2009
Waste Costs without the protocol.
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